← Back to Search

GLP-1 Receptor Agonist

GLUCOSE-MGH Study for Metabolic Diseases (GLUCOSE-MGH Trial)

Phase 4
Recruiting
Led By Josephine Li, MD
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 120 minutes during visit 1
Awards & highlights

GLUCOSE-MGH Trial Summary

This trial aims to understand how genetic differences affect the way the body responds to a medication called oral semaglutide, commonly used to treat diabetes and obesity. Participants will have their blood tested before and

Who is the study for?
This trial is for adults aged 18-50 who can consent and have blood sugar levels indicating they are between normal health and pre-diabetes. It's not suitable for pregnant individuals or those outside the age range.Check my eligibility
What is being tested?
The study tests how genetic differences affect responses to Rybelsus, a diabetes/obesity drug, by analyzing blood factors after a standard meal before and after two weeks of taking the drug.See study design
What are the potential side effects?
While specific side effects aren't listed here, common ones for Rybelsus may include stomach pain, nausea, diarrhea, weight loss, and potential changes in blood sugar levels.

GLUCOSE-MGH Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~120 minutes during visit 1
This trial's timeline: 3 weeks for screening, Varies for treatment, and 120 minutes during visit 1 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Insulin response to oral semaglutide treatment
Secondary outcome measures
Baseline incretin level
Cumulative glucose response to oral semaglutide treatment
Fasting glucose response to oral semaglutide treatment

GLUCOSE-MGH Trial Design

1Treatment groups
Experimental Treatment
Group I: GLUCOSE-MGH StudyExperimental Treatment2 Interventions
Day 1: Mixed meal tolerance test Day 3-15: 7 mg oral semaglutide, once daily Day 16: 1 dose of 7 mg oral semaglutide, Mixed meal tolerance test in the presence of semaglutide

Find a Location

Who is running the clinical trial?

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
2,378 Previous Clinical Trials
4,315,346 Total Patients Enrolled
27 Trials studying Metabolic Diseases
6,114 Patients Enrolled for Metabolic Diseases
Massachusetts General HospitalLead Sponsor
2,945 Previous Clinical Trials
13,203,753 Total Patients Enrolled
6 Trials studying Metabolic Diseases
471 Patients Enrolled for Metabolic Diseases
Josephine Li, MDPrincipal InvestigatorMGH
~83 spots leftby May 2027
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top